T. Rowe Price Associates’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-10,869
| Closed | -$18K | – | 3083 |
|
|
2024
Q1 | $18K | Buy |
10,869
+783
| +8% | +$1.16K | ﹤0.01% | 2933 |
|
|
2023
Q4 | $9K | Sell |
10,086
-34,200
| -77% | -$30K | ﹤0.01% | 2891 |
|
|
2023
Q3 | $48K | Sell |
44,286
-2,677
| -6% | -$5.54K | ﹤0.01% | 2787 |
|
|
2023
Q2 | $122K | Hold |
46,963
| – | – | ﹤0.01% | 2660 |
|
|
2023
Q1 | $192K | Buy |
46,963
+6,776
| +17% | +$31.3K | ﹤0.01% | 2545 |
|
|
2022
Q4 | $202K | Buy |
40,187
+6,242
| +18% | +$39.1K | ﹤0.01% | 2530 |
|
|
2022
Q3 | $445K | Buy |
33,945
+13,505
| +66% | +$205K | ﹤0.01% | 2176 |
|
|
2022
Q2 | $262K | Buy |
20,440
+1,425
| +7% | +$19.7K | ﹤0.01% | 2499 |
|
|
2022
Q1 | $290K | Buy |
19,015
+795
| +4% | +$12.4K | ﹤0.01% | 2560 |
|
|
2021
Q4 | $323K | Sell |
18,220
-366,496
| -95% | -$7.03M | ﹤0.01% | 2575 |
|
|
2021
Q3 | $8.09M | Sell |
384,716
-49,142
| -11% | -$1.08M | ﹤0.01% | 1446 |
|
|
2021
Q2 | $8.56M | Buy |
433,858
+54,395
| +14% | +$1.27M | ﹤0.01% | 1435 |
|
|
2021
Q1 | $11M | Buy |
+379,463
| New | +$10.6M | ﹤0.01% | 1382 |
|
T. Rowe Price Associates's NGM Position: Q2 2024 in Review
T. Rowe Price Associates sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 10,869 shares — an estimated $18K sold.
T. Rowe Price Associates first reported a position in NGM in Q1 2021 and held it in 13 quarters. The position peaked at $11M in Q1 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- T. Rowe Price Associates reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- T. Rowe Price Associates sold 10,869 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $18K.
- T. Rowe Price Associates first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- T. Rowe Price Associates's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $11M in Q1 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.